Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467370 · ClinicalTrials.gov registry record
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 467
- Enrollment target
NCT06467370 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 467 participants.
The verdict
NCT06467370 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 467 participants
- Enrollment target
Study Summary
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2025-03-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06467370
The ClinicalTrials.gov registry entry for NCT06467370 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06467370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06467370 about?
NCT06467370 is a clinical study titled "A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.". This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely ...
What is the current status of trial NCT06467370?
This trial is currently completed. The enrollment target is 467 participants. The study started on 2024-07-02. Estimated completion is 2025-03-11.
Who is sponsoring clinical trial NCT06467370?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.